FEATURED VIDEO – SIOP 2018
Clinical Trials FOR PREVENTION OF CISPLATIN-INDUCED HEARING LOSS: CURRENT STUDY RESULTS, POTENTIAL PRACTICE APPLICATIONS, AND FUTURE CHALLENGES—Dr. David R. Freyer, DO, MS
Featured Video – SIOP 2017
PEDMARKTM (a unique formulation of Sodium Thiosulfate) as otoprotectant to reduce the incidence of cisplatin-induced hearing loss
Recent News
Fennec Pharmaceuticals Announces $12.5 Million Debt Financing With Bridge Bank
RESEARCH TRIANGLE PARK, N.C., Feb. 04, 2019 -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the…
FENNEC PHARMACEUTICALS INITIATES ROLLING NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR PEDMARK™
PEDMARKTM is proposed to be indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age…
FENNEC PHARMACEUTICALS ANNOUNCES SCIENTIFIC SYMPOSIUM ON OTOTOXICITY IN PEDIATRIC CANCER PATIENTS AT THE 50TH CONGRESS OF THE INTERNATIONAL SOCIETY OF PEDIATRIC ONCOLOGY (SIOP) 2018 MEETING
Research Triangle Park, NC, November 16, 2018 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the…